1. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Dexamethasone intravitreal implant. A, Placement of the dexamethasone intravitreal implant in the vitreous. B, Degradation of the implant over time: at administration (left) and after 3 weeks (right).
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

2. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Flowchart of patient disposition. DEX implant indicates dexamethasone intravitreal implant.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

3. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Eyes with a vitreous haze score of 0. A, All eyes. B, Eyes with a baseline vitreous haze score of +1.5 or +2. C, Eyes with a baseline vitreous haze score of +3 or +4. When significant, P values are shown for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs sham. *One patient in the 0.7-mg DEX implant group with a baseline vitreous haze score of +1 was excluded from the analysis.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

4. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Eyes with at least 2 units of improvement in vitreous haze score. When significant, P values are shown for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs sham. The differences between the 0.35-mg DEX implant group and the sham group were statistically significant at week 3 (P = .034) and weeks 6 to 26 (P ≤ .003).
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

5. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Best-corrected visual acuity (BCVA). A, Eyes achieving a 15-letter or more improvement from baseline BCVA. B, Change from baseline BCVA. P > .05 for the 0.7-mg vs 0.35-mg dexamethasone intravitreal implant (DEX implant). P values are in comparison with the sham procedure.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

6. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Cumulative percentage of eyes requiring rescue medication in the study eye at each visit. P values are for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs the sham procedure.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

7. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Percentage of eyes with notable changes in intraocular pressure (IOP). A, Percentage of eyes with IOP of at least 35 mm Hg. B, Percentage of eyes with IOP of at least 25 mm Hg. DEX implant indicates dexamethasone intravitreal implant.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.

8. Copyright © 2011 American Medical Association. All rights reserved.
From: Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Arch Ophthalmol. 2011;129(5): doi: /archophthalmol
Figure Legend:
Intraocular pressure (IOP)–lowering medication use in the 0.7-mg dexamethasone intravitreal implant (DEX implant) group only.
Date of download: 10/6/2017
Copyright © 2011 American Medical Association. All rights reserved.